Detalhe da pesquisa
1.
IMpower210: A phase III study of second-line atezolizumab vs. docetaxel in East Asian patients with non-small cell lung cancer.
Chin J Cancer Res
; 36(2): 103-113, 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38751442
2.
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 23(6): 739-747, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35576956
3.
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol
; 23(2): 209-219, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35038429
4.
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.
Mol Cancer
; 21(1): 4, 2022 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34980131
5.
Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Efficacy, and Biomarkers.
Oncologist
; 2022 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35445725
6.
Peripheral Tumor Location Predicts a Favorable Prognosis in Patients with Resected Small Cell Lung Cancer.
Int J Clin Pract
; 2022: 4183326, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36605462
7.
Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.
Int J Cancer
; 148(9): 2313-2320, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33231285
8.
Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study.
Br J Cancer
; 125(3): 366-371, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34006926
9.
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Invest New Drugs
; 39(2): 477-487, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33052556
10.
A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
BMC Cancer
; 17(1): 462, 2017 Jul 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28673332
11.
A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung.
BMC Cancer
; 14: 684, 2014 Sep 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25239521
12.
Efficacy and safety of utidelone for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who have failed standard second-line treatment: A phase 2 clinical trial (BG01-1801).
Cancer Pathog Ther
; 2(2): 103-111, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38601485
13.
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial.
Lancet Respir Med
; 12(5): 355-365, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38309287
14.
Third-line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, double-blind phase 2 study.
Cancer Innov
; 2(3): 181-190, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38089404
15.
HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non-Small Cell Lung Cancer.
Clin Cancer Res
; 29(23): 4830-4843, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37449971
16.
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study.
Lancet Respir Med
; 11(10): 905-915, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37244266
17.
Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study.
J Cancer Res Clin Oncol
; 149(12): 10771-10780, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37316692
18.
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial.
J Thorac Oncol
; 18(5): 628-639, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36646210
19.
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.
Lung Cancer
; 180: 107194, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163774
20.
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Lancet Oncol
; 12(8): 735-42, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21783417